



Protective activity of Jiang-Zhi-Li-Gan against carbon tetrachloride-induced hepatic injury in mice

Qing Zhai, Xiao-Lan Bian & Bo Yu


To cite this article: Qing Zhai, Xiao-Lan Bian & Bo Yu (2010) Protective activity of Jiang-Zhi-Li-Gan against carbon tetrachloride-induced hepatic injury in mice, *Pharmaceutical Biology*, 48:2, 231-233, DOI: [10.3109/13880200903264442](https://doi.org/10.3109/13880200903264442)

To link to this article: <https://doi.org/10.3109/13880200903264442>



Published online: 25 Jan 2010.




Submit your article to this journal 



Article views: 532



View related articles 

ORIGINAL ARTICLE

Protective activity of Jiang-Zhi-Li-Gan against carbon tetrachloride-induced hepatic injury in mice

Qing Zhai^{1,2}, Xiao-Lan Bian^{3,4}, and Bo Yu^{1,2}

¹Department of Pharmacy, Fudan University Cancer Hospital, Shanghai, China, ²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, ³Department of Pharmacy, Luwan Branch of Rui-Jin Hospital, Shanghai, China, and ⁴Department of Pharmacy, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Abstract

The administration of carbon tetrachloride (CCl₄) to mice produced hepatotoxicity, showing a significant increase in the serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST). Mice pre-treated with Jiang-Zhi-Li-Gan (JZLG, 100–900 mg/kg, p.o.), a domestic remedy for liver disease in Rui-Jin Hospital, showed a significant decrease in serum ALT and AST levels when compared to the group treated with CCl₄ alone. The standard drug, bifendate (200 mg/kg, p.o.), also exhibited similar results. In the acute toxicity study, JZLG did not show any mortality up to a dose of 32 g/kg body weight. Based on the results obtained, it can be concluded that JZLG seems to possess hepatoprotective activity in mice. These results support the use of this prescription against chemical hepatic injury.

Keywords: Carbon tetrachloride; CCl₄; chemical hepatic injury; hepatoprotective; Jiang-Zhi-Li-Gan

Introduction

Jiang-Zhi-Li-Gan (JZLG) comprises: (1) *Radix Bupleuri* (Umbelliferae), the dried roots of *Bupleurum chinense* DC. or *Bupleurum scorzoneri folium* Willd., used for treatment of liver disease in oriental medicine and possessing anti-tumor properties (Kang et al., 2008); (2) *Radix Astragali* (Leguminosae), the dried roots of *Astragalus membranaceus* (Fisch.) Bge. var. *mongholicus* (Bge.) Hsiao or *Astragalus membranaceus* (Fisch.) Bge., widely used for treatment of cardiovascular diseases such as heart failure, angina pectoris, myocardial infarction, and stroke in Asian countries (Zhao et al., 2008); (3) *Fructus Crataegi* (Rosaceae), the dried matured fruits of *Crataegus pinnatifida* Bge. var. *major* N.E. Br. or *Crataegus pinnatifida* Bge., possessing potential against oxidative stress (Chu et al., 2003); (4) *Radix et Rhizoma Salviae Miltiorrhizae* (Labiatae), the dried roots and rhizome of *Salvia miltiorrhiza* Bge. or *Salviae miltiorrhizae Radix* (SMR), an eminent herb in the treatment of

cardiovascular disorder (called blood stasis in traditional Chinese medicine) widely used in China, Japan, Taiwan, and Korea (Koo et al., 2004); (5) *Radix et Rhizoma Rhei* (Polyginaceae), the dried roots and rhizome of *Rheum palmatum* L., *Rheum tanguticum* Maxim. ex Balf., or *Rheum officinale* Baill., having a protective capacity both *in vitro* on primary hepatocyte cultures and *in vivo* in a rat model of CCl₄ mediated liver injury (Ibrahim et al., 2008); and (6) *Radix et Rhizoma Glycyrrhizae* (Leguminosae), the dried roots and rhizome of *Glycyrrhiza uralensis* Fisch., *Glycyrrhiza inflata* Bat., or *Glycyrrhiza glabra* L., having long been used worldwide as a herbal medicine and natural sweetener and as a traditional medicine mainly for the treatment of peptic ulcer, hepatitis C, and pulmonary and skin diseases (Asl & Hosseinzadeh, 2008). This prescription is a remedy for liver disease that has been used in Rui-Jin Hospital for years. However, its effect on carbon tetrachloride (CCl₄) induced liver injury has never been investigated.

Address for Correspondence: Bo Yu, Department of Pharmacy, Fudan University Cancer Hospital, 270 Dong-An Road, Shanghai 200032, China. Tel/fax: +86 21 64431945. E-mail: mikeyumike@hotmail.com

(Received 23 February 2009; revised 12 April 2009; accepted 08 May 2009)

ISSN 1388-0209 print/ISSN 1744-5116 online © 2010 Informa UK Ltd
DOI: 10.3109/13880200903264442

<http://www.informahealthcare.com/phb>

The present study was designed to investigate the effect of JZLG on acute chemical liver injury by CCl_4 in mice.

Materials and methods

Plants

Air-dried plants were supplied by Shanghai Herbal Medicine Co. Ltd. (Shanghai, China). A voucher specimen of each plant is deposited in the Department of Pharmacy, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (reference number 080413:1–6).

Reagents

Alanine transaminase (ALT) and aspartate aminotransferase (AST) assay kits were purchased from Kang-Jian (Shanghai, China). Other chemicals and reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.

Extraction

Deionized water (1 L) was added to 100.0 g of JZLG prescription, comprising 12.8 g of *Radix Bupleuri*, 19.2 g of *Radix Astragali*, 25.6 g of *Fructus Crataegi*, 19.2 g of *Radix et Rhizoma Salviae Miltiorrhizae*, 3.8 g of *Radix et Rhizoma Rhei*, and 19.4 g of *Radix et Rhizoma Glycyrrhizae*, previously ground and sieved through a mesh No. 50, and was heated until the preparation boiled. Boiling was continued for 2 h. The decoction was then percolated to obtain the filtrate, and the dregs were re-boiled with fresh deionized water (1 L) for 1 h. Collected filtrates were then poured together and evaporated in a vacuum to give a dark brown semi-solid extract (yield 32.2%), which was stored at -20°C until use.

Animals

Kun-Ming mice of either sex (weighing 19–21 g) were supplied by Shanghai Slac Laboratory Animal Co. Ltd. (Shanghai, China). The mice were housed in cages under controlled conditions at $20 \pm 3^\circ\text{C}$ and 45–65% humidity with a 12 h light–dark cycle (lights on 6:00 h). Drinking water and food were provided *ad libitum* throughout the study. Animals were acclimatized to their environment for 1 week prior to experimentation. All procedures were performed in accordance with guidelines on the care and use of experimental animals set by Fudan University Cancer Hospital.

Hepatoprotective activity

Hepatic injury was induced in mice by intraperitoneal administration of a single dose of 10 mL/kg 0.1% CCl_4 . Bifendate (biphenyldicarboxylate), a known hepatoprotective agent, was used as the reference standard (Pan et al., 2006).

The 60 mice were grouped randomly as follows:

- Group I: Control group, treated with vehicle (0.2 mL, p.o.) daily for 7 days.
- Group II: Treated with vehicle (0.2 mL, p.o.) daily for 7 days followed by CCl_4 on day 7.
- Group III: Treated with low dose of JZLG (100 mg/kg, p.o.) daily for 7 days followed by CCl_4 on day 7.
- Group IV: Treated with medium dose of JZLG (300 mg/kg, p.o.) daily for 7 days followed by CCl_4 on day 7.
- Group V: Treated with high dose of JZLG (900 mg/kg, p.o.) daily for 7 days followed by CCl_4 on day 7.
- Group VI: Treated with bifendate (200 mg/kg, p.o.) daily for 7 days followed by CCl_4 on day 7.

At the end of the treatment, body weight and relative liver weight were measured; blood samples of each animal were collected in sterile centrifuge tubes and allowed to clot. The serum was separated and used for the assay of marker enzymes (ALT and AST).

Acute toxicity study

Mice were divided into groups of 10 animals each. The control group received saline and the other groups received increasing doses of JZLG extract, respectively. Immediately after dosing, the animals were observed continuously for 7 days to record the mortality.

Statistical analysis

Group mean values and standard deviations were calculated. Data are expressed as mean \pm SD. Statistically significant differences were determined by Student's *t*-test. Differences were considered statistically significant if $p < 0.05$.

Results and discussion

The effects of JZLG on the serum enzymes were investigated and the results are given in Table 1. It is well known that CCl_4 is used as a hepatotoxic agent in various animals (Gopal & Sengottuvelu, 2008). The administration of CCl_4 to mice produced hepatotoxicity, showed by a significant increase in the serum levels of ALT and AST in comparison to the control group. JZLG

Table 1. Effect of JZLG on CCl₄ induced liver damage in mice.

Group	ALT (IU/L)	AST (IU/L)
Group I	55.9 ± 7.8	62.3 ± 10.0
Group II	458.7 ± 85.8 ^{**}	435.9 ± 96.3 ^{**}
Group III	201.3 ± 60.4 ^{**,#}	209.9 ± 30.1 ^{**,#}
Group IV	95.3 ± 60.2 ^{**,##}	185.7 ± 33.7 ^{**,##}
Group V	52.3 ± 12.4 ^{**}	160.7 ± 30.0 ^{**,##}
Group VI	72.5 ± 32.2 ^{*,,##}	210.2 ± 102.3 ^{*,#}

Note. Values are expressed as mean ± SD. * $p < 0.05$, ** $p < 0.01$ compared to Group I; # $p < 0.05$, ## $p < 0.01$ compared to Group II.

Table 2. Body weight and relative liver weight of mice.

Group	Body weight (g)	Relative liver weight (%)
Group I	19.0 ± 1.8	9.9 ± 1.7
Group II	20.9 ± 2.2	9.8 ± 0.9
Group III	20.1 ± 1.1	10.3 ± 1.4
Group IV	20.0 ± 0.9	10.0 ± 1.0
Group V	19.9 ± 0.8	9.9 ± 1.9
Group VI	20.1 ± 0.5	10.9 ± 0.8

Note. Values are expressed as mean ± SD.

caused a significant decrease in the serum enzymes ALT and AST when compared to the CCl₄ group. The standard drug, bifendate (biphenyldicarboxylate, 200 mg/kg, p.o.), also exhibited similar significant results. There were no significant differences in body weight and relative liver weight between all groups (Table 2). In the preliminary acute toxicity study, the JZLG test did not show any mortality up to 32 g/kg (equivalent to 250 times the clinical dose, the maximum administration volume).

On the basis of the results obtained, it can be concluded that JZLG seems to possess hepatoprotective

activity in mice. No toxic symptom or mortality was observed in the 48 h study in mice. These results seem to support the traditional use of this prescription against hepatotoxicity.

Declaration of interest: This work was supported by grant 2006Y002A (to Q.Z.) from the Shanghai Municipal Health Bureau.

References

- Asl MN, Hosseinzadeh H (2008): Review of pharmacological effects of *Glycyrrhiza* sp. and its bioactive compounds. *Phytother Res* 22: 709–724.
- Chu CY, Lee MJ, Liao CL, Lin WL, Yin YF, Tseng TH (2003): Inhibitory effect of hot-water extract from dried fruit of *Crataegus pinnatifida* on low-density lipoprotein (LDL) oxidation in cell and cell-free systems. *J Agric Food Chem* 51: 7583–7588.
- Gopal N, Sengottuvelu S (2008): Hepatoprotective activity of *Clerodendrum inerme* against CCl₄ induced hepatic injury in rats. *Fitoterapia* 79: 24–26.
- Ibrahim M, Khaja MN, Aara A, Khan AA, Habeeb MA, Devi YP, Narasu ML, Habibullah CM (2008): Hepatoprotective activity of *Sapindus mukorossi* and *Rheum emodi* extracts: *In vitro* and *in vivo* studies. *World J Gastroenterol* 14: 2566–2571.
- Kang SJ, Lee YJ, Kim BM, Kim YJ, Woo HD, Jeon HK, Chung HW (2008): Effect of *Bupleuri Radix* extracts on the toxicity of 5-fluorouracil in HepG2 hepatoma cells and normal human lymphocytes. *Basic Clin Pharmacol Toxicol* 103: 305–313.
- Koo BS, Kwon TS, Kim CH (2004): *Salviae miltiorrhizae radix* inhibits superoxide generation by activated rat microglia and mimics the action of amphetamine on *in vitro* rat striatal dopamine release. *Neurochem Res* 29: 1837–1845.
- Pan SY, Yang R, Dong H, Yu ZL, Ko KM (2006): Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. *Eur J Pharmacol* 552: 170–175.
- Zhao P, Su G, Xiao X, Hao E, Zhu X, Ren J (2008): Chinese medicinal herb *Radix Astragali* suppresses cardiac contractile dysfunction and inflammation in a rat model of autoimmune myocarditis. *Toxicol Lett* 182: 29–35.